Compare TK & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | CMPX |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 927.5M |
| IPO Year | 1995 | 2020 |
| Metric | TK | CMPX |
|---|---|---|
| Price | $13.47 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 446.5K | ★ 12.2M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $1.61 |
| 52 Week High | $14.38 | $6.88 |
| Indicator | TK | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 26.23 |
| Support Level | $12.09 | $1.61 |
| Resistance Level | $13.76 | $3.54 |
| Average True Range (ATR) | 0.50 | 0.15 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 39.74 | 46.05 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.